跳至主要内容
临床试验/CTIS2024-513671-40-00
CTIS2024-513671-40-00进行中(未招募)1 期

VAC-WARTS Efficacy of the nonavalent HPV vaccine in the treatment of difficult-to-treat palmo-plantar warts - APHP200046

Assistance Publique Hopitaux De Paris0 个研究点目标入组 146 人开始时间: 2024年6月25日最近更新:
适应症

试验速览

阶段
1 期
状态
进行中(未招募)
入组人数
146

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional clinical trial of medicinal product

入排标准

年龄范围
0 至 65+(—)
性别
All

入选标准

  • Patients of age = 15 years and 3 months with palmar or plantar warts (including periungueal and back of hands or feet warts) since more than one year with: - = 5 warts (X palmar and X plantar) or - = 4 cm2 of Total surface involved by the warts (Y cm x Z cm)., Patients should have received two lines of treatment during the past year before inclusion, the last treatment must be at 3 weeks maximum before inclusion:, Painful warts (VAS = 4) or functional discomfort (Revised foot function index (RFFI) or Cochin Hand Function Scale (CHSF) or social discomfort (DLQI))., No systemic immunosuppresive/ immunomodulating drugs, Women of childbearing potential must have a negative pregnancy test and an effective contraception (V1) and up the end of the vaccination period of 6 months;, Individuals affiliated to a social security regimen;, Individuals able to participate and to follow up during the study period

排除标准

  • Suspicion of COVID, with confirmation by autotest, Women who are pregnant or are breast-feeding, or are of childbearing age who have not used or do not plan to use acceptable birth control measures, during the first 6 months ½ of the study, Individuals under a measure of legal protection or unable to consent;, Individuals participating in any clinical trial with another investigational product 28 days prior to first study visit or intent to participate in another clinical study at any time during the conduct of the study, Participation in another interventional study involving human participants or being in the exclusion period at the end of a previous study involving human participants, if applicable, Patient on AME (state medical aid) (unless exemption from affiliation)., Patient wishing to be vaccinated with Gardasil 9® within 6 months (in accordance to the approval of the vaccine) or refusing the principle of postponing vaccination., Immunosuppressive therapy including use of systemic corticosteroids or chronic immunosuppressant medication (more than 14 days), Any causes of immunosupression: organ transplant recipients, bone-marrow transplantation, immunosupressive regimens for any diseases, HIV positivity., Women or men who received HPV Vaccine previously of the study;, Any serious chronic or progressive disease according to the judgement of the investigator;, Individuals with history of known allergies/hypersensitivity to any component of study vaccine;, Individuals who have any malignancy or lymphoproliferative disorder;, Individuals with thrombocytopenia or coagulation disorder contre-indicating intramusculary injections;, Patient with anticoagulant therapy, Individuals with body temperature > 38.0 degrees Celsius or/and acute disease within 3 days of intended study vaccination;

研究者

相似试验